Research & Development
Pathology & AI
Gene silencing and gene editing: Page 2
Anitoa launches portable test for dengue virus
The multiplex test, part of the company's Maverick line of RT-PCR devices, detects several target genes in a sample which have been shown by researchers to be highly expressed in patients who later develop serious symptoms, the company said.
May 4, 2022
Agendia highlights presentations at ESMO Breast Cancer 2022
The first poster presentation concluded that the next-generation sequencing versions of MammaPrint and BluePrint are equivalent to a centralized microarray test, according to the vendor.
May 3, 2022
iCura given CRO status by Akoya Biosciences
iCura provides diagnostic testing and services for the pharmaceutical industry, academic research centers, and partner CROs and laboratories. The company has recently focused its services on multiplexing immunofluorescence (IF)/immunohistochemistry (IHC), circulating tumor cells, and genomic services.
April 17, 2022
Ultivue, Paige partner to advance AI products
Efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue's novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels, the companies said.
April 7, 2022
Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
Lunaphore, MGH collaborate on IVD work for solid tumors
The collaboration will focus on ovarian, breast, and prostate cancers. The two entities will work together to develop a multiplexed immunofluorescence assay that will measure multiple protein expression.
February 17, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
Widespread HbA1c screening enables earlier type 2 diabetes diagnosis in U.K. study
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
FDA grants EUA for Lucira Health’s COVID-19 and flu combination test
Wellcome Institute touts COVID sequencing data at SLAS 2022
As part of WSI's sequencing work, the institute is developing and scaling an automated pipeline to produce SARS-CoV-2 libraries to support multiplexed sequencing on the Illumina NovaSeq platform, according to the poster.
February 3, 2022
Rheonix gets FDA nod for STI test, workstation
The Encompass MDx workstation enables scalable, multiplexed sample-to-answer detection, simplifying laboratory workflows.
January 11, 2022
Eurofins debuts 2 combined tests for COVID/influenza, RSV
The new multiplex kits have been granted the CE Mark and are designed to detect and differentiate three viral infections in the same PCR run, Eurofins said.
November 30, 2021
Hologic launches multiplex COVID/flu assay
The three viruses can present with overlapping clinical symptoms, Hologic said. The new assay runs on Hologic's fully automated Panther system, which can provide initial results in approximately three hours and can process more than 1,000 tests in 24 hours, the company said.
October 27, 2021
Hologic launches on-demand molecular testing in Europe
Novodiag features real-time polymerase chain reaction and microarray capabilities that allow for multiple pathogens to be identified from a single sample, Hologic said. Its CE-marked IVD test menu includes assays for gastrointestinal infection, antibiotic resistance, and SARS-CoV-2.
October 5, 2021
Nonagen's Oncuria granted FDA designation
The company said Oncuria is capable of predicting how a patient will respond to therapy. The multiplex immunoassay measures 10 protein biomarkers in a single voided urine sample.
September 30, 2021
Page 2 of 5